NR4A3
Overview
NR4A3 (Nuclear Receptor Subfamily 4 Group A Member 3, also known as NOR1 or CHN) is a member of the NR4A orphan nuclear receptor family that functions as a transcription factor. NR4A3 has been implicated in various cancers; notably, fusions involving NR4A3 are oncogenic driver events observed in myxoid chondrosarcoma and, as identified in the MET500 pan-cancer study, novel fusion configurations in additional tumor types.
Alterations observed in the corpus
- Novel GREB1-NR4A3 activating fusion identified in uterine leiomyosarcoma (ULMS) in the MET500 500-patient pan-cancer metastatic cohort; represents an expansion of the NR4A3 fusion landscape beyond its canonical myxoid chondrosarcoma context PMID:28783718.
Cancer types (linked)
- Uterine leiomyosarcoma (ULMS): novel GREB1-NR4A3 activating fusion identified PMID:28783718.
Co-occurrence and mutual exclusivity
- The GREB1-NR4A3 fusion was identified as a novel cancer driver event in the context of pan-cancer fusion landscape analysis PMID:28783718.
Therapeutic relevance
- Activating NR4A3 fusions may be targetable by analogy to other oncogenic fusion kinases, though no specific therapeutic data are reported for this fusion PMID:28783718.
Open questions
- Prevalence and functional validation of GREB1-NR4A3 in ULMS and other sarcoma types require further study.
Sources
This page was processed by crosslinker on 2026-05-15.